» Articles » PMID: 35632507

Vaccination Against Bacterial Infections: Challenges, Progress, and New Approaches with a Focus on Intracellular Bacteria

Overview
Date 2022 May 28
PMID 35632507
Authors
Affiliations
Soon will be listed here.
Abstract

Many bacterial infections are major health problems worldwide, and treatment of many of these infectious diseases is becoming increasingly difficult due to the development of antibiotic resistance, which is a major threat. Prophylactic vaccines against these bacterial pathogens are urgently needed. This is also true for bacterial infections that are still neglected, even though they affect a large part of the world's population, especially under poor hygienic conditions. One example is typhus, a life-threatening disease also known as "war plague" caused by , which could potentially come back in a war situation such as the one in Ukraine. However, vaccination against bacterial infections is a challenge. In general, bacteria are much more complex organisms than viruses and as such are more difficult targets. Unlike comparatively simple viruses, bacteria possess a variety of antigens whose immunogenic potential is often unknown, and it is unclear which antigen can elicit a protective and long-lasting immune response. Several vaccines against extracellular bacteria have been developed in the past and are still used successfully today, e.g., vaccines against tetanus, pertussis, and diphtheria. However, while induction of antibody production is usually sufficient for protection against extracellular bacteria, vaccination against intracellular bacteria is much more difficult because effective defense against these pathogens requires T cell-mediated responses, particularly the activation of cytotoxic CD8 T cells. These responses are usually not efficiently elicited by immunization with non-living whole cell antigens or subunit vaccines, so that other antigen delivery strategies are required. This review provides an overview of existing antibacterial vaccines and novel approaches to vaccination with a focus on immunization against intracellular bacteria.

Citing Articles

Leveraging Electron Beam (eBeam) Technology for Advancing the Development of Inactivated Vaccines.

Perera R, Pillai S, Alrubaye A, Jesudhasan P Vaccines (Basel). 2025; 13(2).

PMID: 40006726 PMC: 11861765. DOI: 10.3390/vaccines13020179.


The United Nations' ambitious roadmap against tuberculosis: opportunities, challenges and the imperative of equity.

Gulumbe B, Abdulrahim A, Danlami M Future Sci OA. 2024; 10(1):2418787.

PMID: 39539153 PMC: 11572144. DOI: 10.1080/20565623.2024.2418787.


A Novel Newborn Screening Program for Sickle Cell Disease in Nigeria.

Galadanci A, Ibrahim U, Carroll Y, Jobbi Y, Farouk Z, Mukaddas A Int J Neonatal Screen. 2024; 10(4).

PMID: 39449355 PMC: 11503303. DOI: 10.3390/ijns10040067.


mRNA vaccines for infectious diseases - advances, challenges and opportunities.

Pardi N, Krammer F Nat Rev Drug Discov. 2024; 23(11):838-861.

PMID: 39367276 DOI: 10.1038/s41573-024-01042-y.


Therapeutic Strategies to Combat Increasing Rates of Multidrug Resistant Pathogens.

Vitiello A, Rezza G, Silenzi A, Salzano A, Alise M, Boccellino M Pharm Res. 2024; 41(8):1557-1571.

PMID: 39107513 DOI: 10.1007/s11095-024-03756-5.


References
1.
Noriea N, Clark T, Hackstadt T . Targeted knockout of the Rickettsia rickettsii OmpA surface antigen does not diminish virulence in a mammalian model system. mBio. 2015; 6(2). PMC: 4453529. DOI: 10.1128/mBio.00323-15. View

2.
MacLennan C, Martin L, Micoli F . Vaccines against invasive Salmonella disease: current status and future directions. Hum Vaccin Immunother. 2014; 10(6):1478-93. PMC: 4185946. DOI: 10.4161/hv.29054. View

3.
Russmann H, Igwe E, Sauer J, Hardt W, Bubert A, Geginat G . Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. J Immunol. 2001; 167(1):357-65. DOI: 10.4049/jimmunol.167.1.357. View

4.
Leung-Theung-Long S, Coupet C, Gouanvic M, Schmitt D, Ray A, Hoffmann C . A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis. PLoS One. 2018; 13(5):e0196815. PMC: 5931632. DOI: 10.1371/journal.pone.0196815. View

5.
Sun T, Holowka T, Song Y, Zierow S, Leng L, Chen Y . A Plasmodium-encoded cytokine suppresses T-cell immunity during malaria. Proc Natl Acad Sci U S A. 2012; 109(31):E2117-26. PMC: 3411961. DOI: 10.1073/pnas.1206573109. View